ozempic

Latest news and analysis on ozempic

Equities

Ozempic first mover sheds $170B in 4 days: Here's 2 ideas we're backing instead

After crashing more than 30% this week, Novo Nordisk has now seen its share price fall 65% over the last 12 months.
+1
Arms Rosenberg
Minotaur Capital
Equities

Ozempic and beyond, inside the weight loss drug revolution

In this episode of "Inside the Rope," host David Clark welcomes back Dr. Craig Collie from Regal Funds Management to delve into the groundbreaking developments in the...
David Clark
Koda Capital
Equities

What will be the biggest selling drug of all-time?

We weigh the latest blockbuster weight-loss drugs against pharmaceuticals (and others) that have gone before
+3
Ted Alexander
BML Funds
Funds

The weight is over: obesity drugs have arrived

Breakthroughs in obesity drugs look extraordinarily profitable for 2 stocks. But, with improvements, a raft of sectors might be affected.
Damien Klassen
Nucleus Wealth
Education

Ozempic – Is Novo Nordisk’s diabetes and weight loss drug a miracle or a menace?

In a society riddled with low self-esteem and mental health issues, weight loss can be a controversial and difficult topic. Pop culture and social media do more harm...
Ted Franks
Pengana Capital Group
5